Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recent progress in drug development for fibrodysplasia ossificans progressiva.

Molecular and cellular biochemistry - 1 Oct 2022

Meng Xinmiao, Wang Haotian, Hao Jijun

Abstract excerpt

Fibrodysplasia Ossificans Progressiva (FOP) is a rare genetic disease caused by heterozygous missense mutations in Activin A receptor type I which is also known as Activin-like kinase 2 (ALK2), a type I receptor of Bone Morphogenetic Proteins(BMP). Patients with FOP usually undergo episodic flare-ups and the heterotopic ossification in soft and connective tissues. Molecular mechanism study indicates that Activin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Activins
Share to Bone Morphogenetic Proteins
Share to Drug Development

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Ligands

Share to Mutation

Share to Myositis Ossificans

Share to Ossification, Heterotopic

Share to Transforming Growth Factor beta

Source

Open in PubMed Open full text

Identifiers

PMID: 35536530
DOI: 10.1007/s11010-022-04446-9
PMCID: PMC9499916

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recent progress in drug development for fibrodysplasia ossificans progressiva.PMID 35536530Read ↗

From mysteries to medicines: drug development for fibrodysplasia ossificans progressivaSemantic proximity Read ↗

Challenges and Opportunities for Drug Repositioning in Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

Recent Topics in Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

A new era for fibrodysplasia ossificans progressiva: a druggable target for the second skeleton.Semantic proximity Read ↗

Fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

Clinical Aspects and Current Therapeutic Approaches for FOPSemantic proximity Read ↗

The Horizon of a Therapy for Rare Genetic Diseases: A “Druggable” Future for Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

How Activin A Became a Therapeutic Target in Fibrodysplasia Ossificans ProgressivaSemantic proximity Read ↗

Twists in the fibrodysplasia ossificans progressiva story challenge and expand our understanding of BMP biology.Semantic proximity Read ↗

Disease-causing allele-specific silencing against the ALK2 mutants, R206H and G356D, in fibrodysplasia ossificans progressiva.Semantic proximity Read ↗

A Door Opens for Fibrodysplasia Ossificans Progressiva.Semantic proximity Read ↗

Garetosmab, an inhibitor of activin A, reduces heterotopic ossification and flare-ups in adults with fibrodysplasia ossificans progressiva: a randomized, double-blind, placebo-controlled phase 2 trialSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.